Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2020
Shionogi’s novel antibiotic, Fetcroja (cefiderocol), has been selected by UK’S NICE/NHSE&I as part of an antimicrobial subscription style reimbursement model
21 December 2020 - NICE and the National Health Service England and Improvement have recognised the potential of Shionogi’s innovative ...
Posted by Michael Wonder on 22 Dec 2020
FDA approves paediatric indication for Xeomin (incobotulintoxinA) for the treatment of chronic sialorrhoea
21 December 2020 - Xeomin is the first and only neuromodulator approved in the U.S. to treat paediatric patients with chronic ...
Posted by Michael Wonder on 22 Dec 2020
FDA approves treatment for Ebola virus
21 December 2020 - The U.S. FDA approved Ebanga (Ansuvimab-zykl), a human monoclonal antibody, for the treatment for Zaire ebolavirus (Ebolavirus) ...
Posted by Michael Wonder on 22 Dec 2020
Jazz Pharmaceuticals announces initiation of biologics license application submission for JZP-458 for the treatment of acute lymphoblastic leukaemia or lymphoblastic lymphoma
21 December 2020 - Application to be reviewed under FDA's Oncology Center of Excellence Real-Time Oncology Review pilot program. ...
Posted by Michael Wonder on 21 Dec 2020
Price disclosure 2021 April cycle outcomes summary
21 December 2020 - The summary of price disclosure price reductions for the 2021 April Cycle has now been published. ...
Posted by Michael Wonder on 21 Dec 2020
Vertex announces FDA approvals of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor and ivacaftor) and Kalydeco (ivacaftor) for use in people with cystic fibrosis with certain rare mutations
21 December 2020 - More than 600 people with certain rare cystic fibrosis mutations are now eligible for Trikafta, Symdeko or ...
Posted by Michael Wonder on 21 Dec 2020
European Commission approves Aimmune’s Palforzia as first-ever treatment for peanut allergy in the EU
21 December 2020 - Peanut allergy is one of the most common food allergies in Europe. ...
Posted by Michael Wonder on 21 Dec 2020
Swissmedic approves Buvidal for the treatment of opioid dependence
18 December 2020 - Camurus announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ...
Posted by Michael Wonder on 21 Dec 2020
PBS website updates for Stage 2 PBS process improvements
21 December 2020 - The PBS website has been updated to support implementation of Stage 2 PBS process improvements from ...
Posted by Michael Wonder on 21 Dec 2020
Kiwis going into debt to pay for drugs other countries fund
21 December 2020 - An internal stoush at the drug-buying agency PHARMAC has blocked funding for a life-extending drug for bowel ...
Posted by Michael Wonder on 21 Dec 2020
Oyster Point Pharma submits new drug application to the U.S. FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease
18 December 2020 - The new drug application submission is based on efficacy and safety results from a comprehensive clinical trial ...
Posted by Michael Wonder on 21 Dec 2020
PHARMAC to fund new diabetes medicines with amended Special Authority criteria
21 December 2020 - PHARMAC has approved funding for two new medicines with substantial health benefits for around 53,000 New Zealanders ...
Posted by Michael Wonder on 21 Dec 2020
Health Canada approves expanded indication for Soliqua
18 December 2020 - New indication for Soliqua offers an alternative approach for Canadians living with type 2 diabetes requiring treatment ...
Posted by Michael Wonder on 21 Dec 2020
Expanded PBS access to breakthrough medicine for lung cancer
20 December 2020 - A significant lung cancer treatment option that costs approximately $88,000 a year will soon be available for ...
Posted by Michael Wonder on 21 Dec 2020
U.S. FDA approves supplemental new drug application for Takeda’s Iclusig (ponatinib) for adult patients with resistant or intolerant chronic phase CML
19 December 2020 - Approval based on data from the Phase 2 OPTIC trial, which evaluated response-based Iclusig dosing regimens in ...